September 2023

At separate live virtual events, Brea C. Lipe, MD, and Amandeep Godara, MD, MBBS, discussed options for the same elderly patient with multiple myeloma who is not able to receive a transplant.

Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.

During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with participants what factors influence the choice of first-line immunotherapy for a patient with BRAF–wild-type metastatic melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid dendritic cell neoplasm.

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas W. Sborov, MD, MS, discussed treatment after a second relapse in a patient with multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tycel J. Phillips, MD, and participants discussed treatment options for a patient with diffuse large B-cell lymphoma who progressed after 8 months on first-line therapy and prefers to receive outpatient therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed with participants how they would treat a patient with small cell lung cancer after prior treatment with carboplatin plus etoposide.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ulka Vaishampayan, MD, discussed the TIVO-3 study of tivozanib for patients with recurrent advanced renal cell carcinoma.

In an interview with Targeted Oncology™, Alicia K. Morgans, MD, MPH, discussed how the survivorship program at Dana-Farber Cancer Institute helps patients with cancer and ways to incorporate aspects of a survivorship program into more academic and community institutions.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the potency of immunotherapy and tyrosine kinase inhibitor combinations for patients with metastatic renal cell carcinoma.